Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Center for Nontuberculous Mycobacteria and Bronchiectasis, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0058524. doi: 10.1128/aac.00585-24. Epub 2024 Jun 5.
Individuals with compromised lung function and immunity are susceptible to developing chronic infection. Current treatment recommendations typically involve using one β-lactam antibiotic in combination with non-β-lactam antibiotics. However, a recent case study (B. Becken, K. M. Dousa, J. L. Johnson, S. M. Holland, and R. A. Bonomo, Antimicrob Agents Chemother 68:e00319-24, 2024, https://doi.org/10.1128/aac.00319-24) demonstrated successful treatment of chronic lung disease in a child using two β-lactam antibiotics simultaneously. This commentary reviews the emerging evidence and outstanding questions regarding dual β-lactam therapy for infections.
个体的肺功能和免疫受损易导致慢性感染。目前的治疗建议通常包括使用一种β-内酰胺类抗生素与非β-内酰胺类抗生素联合治疗。然而，最近的一项病例研究（B. Becken、K. M. Dousa、J. L. Johnson、S. M. Holland 和 R. A. Bonomo，Antimicrob Agents Chemother 68:e00319-24, 2024, https://doi.org/10.1128/aac.00319-24）表明，同时使用两种β-内酰胺类抗生素可成功治疗儿童慢性肺部疾病。本评论综述了双β-内酰胺类抗生素治疗感染的新出现证据和未解决问题。
